SCHEMBL257337

SCHEMBL257337

Cc1ccc2c(c1)OCC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRNB2 P17787 1/20 0.43
CHRM3 P20309 1/20 0.43
CHRNA4 P43681 1/20 0.43
EGFR P00533 1/20 0.40
PDGFRA P16234 1/20 0.40
KDR P35968 1/20 0.40
PRKCI P41743 1/20 0.39
KCNH2 Q12809 1/20 0.39
PKM P14618 1/20 0.38
OGA O60502 1/20 0.36
DYRK1A Q13627 1/20 0.36
PDE2A O00408 1/20 0.35
PARP1 P09874 1/20 0.35
PARP10 Q53GL7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30236532 1.00 ALDH1A1 (0.44) ALDH1A1GAAMAPTHSD17B10CHRM2
SCHEMBL436669 0.88 KCNH2 (0.49) ALDH1A1GAAMAPTHSD17B10KCNH2
SCHEMBL25763033 0.86 KCNH2 (0.48) ALDH1A1GAAMAPTHSD17B10CHRM2
SCHEMBL11903 0.83 PRKCI (0.52) ALDH1A1GAAMAPTHSD17B10EGFR
SCHEMBL30467099 0.83 PRKCI (0.52) ALDH1A1GAAMAPTHSD17B10EGFR
SCHEMBL28222915 0.80 PIK3CA (0.43) ALDH1A1GAAMAPTHSD17B10PRKCI
SCHEMBL8577915 0.79 ALDH1A1 (0.34) ALDH1A1GAAMAPTHSD17B10PARP1
SCHEMBL14409815 0.79 CYP2A6 (0.46) ALDH1A1GAAMAPTHSD17B10EGFR
SCHEMBL22681819 0.79 EGFR (0.54) ALDH1A1GAAMAPTHSD17B10CHRM2
SCHEMBL8251512 0.78 MAPT (0.41) ALDH1A1GAAMAPTHSD17B10PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US claimed
US-7169775-B2 Amino methyl imidazoles as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-01-30 US claimed
EP-1490343-A1 NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS Neurogen Corporation (US) 2004-12-29 EP claimed
US-20040116424-A1 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION 2004-06-17 US claimed
US-20040082577-A1 Amino methyl imidazoles as C5a receptor modulators NEUROGEN CORPORATION 2004-04-29 US claimed
WO-2004018460-A1 AMINO METHYL IMIDAZOLES AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2004-03-04 WO claimed
WO-2003082829-A1 NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2003-10-09 WO claimed
US-12552793-B2 Purine derivative and medical use thereof KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2026-02-17 US disclosed
WO-2025049746-A1 COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
US-20240209004-A1 BORIC ACID DERIVATIVE ACTING AS Beta-LACTAMASE INHIBITOR TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) 2024-06-27 US disclosed
WO-2024137813-A1 MODULATORS OF MITOCHONDRIAL DNA REPLICATION PRETZEL THERAPEUTICS, INC. (US) 2024-06-27 WO disclosed
WO-2024086361-A1 MOLECULAR GLUE DEGRADER COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2024-04-25 WO disclosed
WO-2024059845-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-21 WO disclosed
EP-0994877-A1 IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Du Pont Pharmaceuticals Company (US) 2000-04-26 EP disclosed
WO-1999001454-A1 IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS DU PONT PHARMACEUTICALS COMPANY (US) 1999-01-14 WO disclosed
EP-0132130-B1 AROYL BENZOFURAN AND BENZOTHIOPHENE ACETIC AND PROPIONIC ACIDS PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SYNTEX (U.S.A.) INC. (US) 1990-03-07 EP disclosed
US-4816473-A ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS SYNTEX (U.S.A.) INC. (US) 1989-03-28 US disclosed
US-4780480-A ANALGESICS, ANTIINFLAMMATORY AGENTS SYNTEX (U.S.A.) INC. (US) 1988-10-25 US disclosed
EP-0132130-A2 Aroyl benzofuran and benzothiophene acetic and propionic acids processes for their production and pharmaceutical compositions containing them SYNTEX (U.S.A.) INC. (US) 1985-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552793-B2 Purine derivative and medical use thereof PNP, CYP2D6, ADORA1 ALDH1A1 755/4885GAA 2641/4885MAPT 4622/4885
US-20240209004-A1 BORIC ACID DERIVATIVE ACTING AS Beta-LACTAMASE INHIBITOR TREH, ME1, BCAT2 ALDH1A1 770/4885GAA 52/4885MAPT 454/4885
US-20040082577-A1 Amino methyl imidazoles as C5a receptor modulators C5AR1, C5AR2, C3AR1 ALDH1A1 3627/4885GAA 4885/4885MAPT 4173/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR ALDH1A1 4757/4885GAA 2162/4885MAPT 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.